AveXis Company Profile (NASDAQ:AVXS)

About AveXis

AveXis logoAveXis, Inc., formerly Biolife Cell Bank, Inc., is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company's product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either carry a mutation in their SMN1 gene or their SMN1 genes have been deleted. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels. It also focuses to develop AVXS-101 to treat additional SMA types and other treatments for rare neurological genetic diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AVXS
  • CUSIP:
Key Metrics:
  • Previous Close: $59.38
  • 50 Day Moving Average: $55.46
  • 200 Day Moving Average: $49.71
  • 52-Week Range: $18.12 - $72.72
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.67
  • P/E Growth: -0.97
  • Market Cap: $1.59B
  • Outstanding Shares: 27,676,000
Profitability:
  • Return on Equity: -46.72%
  • Return on Assets: -43.63%
Debt:
  • Current Ratio: 15.21%
  • Quick Ratio: 15.21%
Additional Links:
Companies Related to AveXis:

Analyst Ratings

Consensus Ratings for AveXis (NASDAQ:AVXS) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $73.87 (28.44% upside)

Analysts' Ratings History for AveXis (NASDAQ:AVXS)
Show:
DateFirmActionRatingPrice TargetDetails
2/7/2017Chardan CapitalReiterated RatingBuy$85.00 -> $100.00View Rating Details
12/29/2016BMO Capital MarketsReiterated RatingOutperform$85.00 -> $78.33View Rating Details
11/14/2016Jefferies Group LLCReiterated RatingBuy$71.00 -> $79.00View Rating Details
11/14/2016Stifel NicolausInitiated CoverageHold$65.00View Rating Details
10/21/2016Bank of America CorpInitiated CoverageBuyView Rating Details
8/17/2016Wells Fargo & CompanyUpgradeMarket Perform -> OutperformView Rating Details
5/13/2016Goldman Sachs Group, Inc. (The)Boost Price TargetBuy$28.00 -> $47.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for AveXis (NASDAQ:AVXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2017        
11/10/2016Q3 2016($0.69)($0.87)ViewListenView Earnings Details
8/11/2016Q216($0.77)($0.68)ViewListenView Earnings Details
5/12/2016Q1($0.35)($1.24)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AveXis (NASDAQ:AVXS)
Current Year EPS Consensus Estimate: $-3.51 EPS
Next Year EPS Consensus Estimate: $-3.45 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.70)($0.70)($0.70)
Q4 20161($0.63)($0.63)($0.63)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AveXis (NASDAQ:AVXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AveXis (NASDAQ:AVXS)
Institutional Ownership Percentage: 68.31%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/13/2016Paul B ManningInsiderSell289,855$34.50$9,999,997.50View SEC Filing  
2/17/2016Bong Y KohDirectorBuy100,000$20.00$2,000,000.00View SEC Filing  
2/17/2016James E FlynnInsiderBuy750,317$19.47$14,608,671.99View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AveXis (NASDAQ:AVXS)
DateHeadline
News IconAveXis Inc AVXS Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:AVXS)
www.bioportfolio.com - February 20 at 9:24 AM
thestreet.com logo3 Stocks Setting Up for Major Breakouts (NASDAQ:AVXS)
www.thestreet.com - February 17 at 6:23 PM
finance.yahoo.com logoAveXis Appoints Rick Modi as Senior Vice President and Chief Business Officer (NASDAQ:AVXS)
finance.yahoo.com - February 16 at 8:38 AM
News IconShares in Focus: AveXis, Inc. (NASDAQ:AVXS) - Midway Monitor (NASDAQ:AVXS)
midwaymonitor.com - February 14 at 9:28 PM
bizjournals.com logoResearch Reports Coverage on Biotech Stocks -- Cerulean Pharma, AveXis, TG Therapeutics, and Aralez Pharma (NASDAQ:AVXS)
www.bizjournals.com - February 9 at 1:44 AM
us.rd.yahoo.com logoAveXis Announces Single-Arm Design for European Pivotal Study of AVXS-101 in SMA Type 1 Patients (NASDAQ:AVXS)
us.rd.yahoo.com - February 7 at 1:51 AM
marketexclusive.com logoAVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Other Events - Market Exclusive (NASDAQ:AVXS)
marketexclusive.com - February 6 at 3:47 PM
News IconIncrease in Volatility Draws Attention to Shares of AveXis, Inc. (:AVXS) - Nelson Research (NASDAQ:AVXS)
nelsonobserver.com - February 2 at 3:48 PM
News IconShares of AveXis, Inc. (AVXS) Sees Large Inflow of Net Money Flow - Morning Outlook (NASDAQ:AVXS)
www.morningoutlook.com - February 2 at 3:48 PM
News IconStock Vacillating as Volatility Hits a High Point For AveXis, Inc. (:AVXS) - Wall Street Beacon (NASDAQ:AVXS)
wsbeacon.com - January 31 at 9:00 PM
finance.yahoo.com logoAveXis Gene Therapy AVXS-101 Granted Access into EMA PRIME Program for Spinal Muscular Atrophy Type 1 (NASDAQ:AVXS)
finance.yahoo.com - January 31 at 3:58 PM
finance.yahoo.com logo8:03 am AveXis: EMA has granted access into its PRIME program for its proprietary gene therapy, AVXS-101, for the treatment of spinal muscular atrophy Type 1; intends to initiate a pivotal trial of AVXS-101 in patients with SMA Type 1 in th (NASDAQ:AVXS)
finance.yahoo.com - January 31 at 3:58 PM
News IconStocks Wilt on Friday But Pull Off Positive Week, How Did This One Fare: AveXis, Inc. (:AVXS) - Wall Street Beacon (NASDAQ:AVXS)
wsbeacon.com - January 29 at 8:45 PM
News IconTrading Circle: Narrowing in on Shares of AveXis, Inc. (NASDAQ:AVXS) - The Tribune (NASDAQ:AVXS)
lakecitytribune.com - January 29 at 8:45 PM
News IconValue Composite Score Update on AveXis, Inc. (NASDAQ:AVXS) - The Tribune (NASDAQ:AVXS)
lakecitytribune.com - January 28 at 8:46 PM
News IconInvestors are Keeping Tabs on AveXis, Inc. (NASDAQ:AVXS) - The Tribune (NASDAQ:AVXS)
lakecitytribune.com - January 27 at 9:55 PM
News IconChardan Capital Markets Sees AveXis (AVXS) with 81% Upside - Economic Calendar (NASDAQ:AVXS)
www.economiccalendar.com - January 27 at 9:55 PM
News IconRoaring Ahead Mid-Session: Stock on Winner's List: AveXis, Inc. (:AVXS) - Aiken Advocate (NASDAQ:AVXS)
aikenadvocate.com - January 26 at 4:11 PM
News IconStock Seesawing as Volatility Sweeps in on AveXis, Inc. (:AVXS) - Wall Street Beacon (NASDAQ:AVXS)
wsbeacon.com - January 26 at 4:11 PM
News IconF-Score in Review on Shares of AveXis, Inc. (NASDAQ:AVXS) - The Tribune (NASDAQ:AVXS)
lakecitytribune.com - January 25 at 2:17 AM
News IconInstitutions Taking Notice Of This Stock in Q4: AveXis, Inc. (:AVXS) - Wall Street Beacon (NASDAQ:AVXS)
wsbeacon.com - January 21 at 3:40 PM
News IconAveXis Inc AVXS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:AVXS)
www.bioportfolio.com - January 17 at 9:29 PM
biz.yahoo.com logoAVEXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:AVXS)
biz.yahoo.com - January 9 at 4:50 PM
nasdaq.com logoREGENXBIO Provides Year-End 2016 Corporate Update (NASDAQ:AVXS)
www.nasdaq.com - January 6 at 3:52 PM
globenewswire.com logoAveXis to Present at the 35th Annual J.P. Morgan Healthcare ... - GlobeNewswire (press release) (NASDAQ:AVXS)
globenewswire.com - January 3 at 4:34 PM
finance.yahoo.com logoAveXis to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:AVXS)
finance.yahoo.com - January 3 at 8:36 AM
News IconACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) , AveXis Inc (NASDAQ:AVXS) - ODF Report (NASDAQ:AVXS)
odfreport.com - December 31 at 3:43 PM
smarteranalyst.com logoChardan Bullish on AveXis Inc (AVXS) Following Rival Spinraza Broad-Label Approval (NASDAQ:AVXS)
www.smarteranalyst.com - December 30 at 4:01 PM
forbes.com logoBiotech's Top 3 Stock Losers, and Winners, in 2016 (NASDAQ:AVXS)
www.forbes.com - December 30 at 4:01 PM
investors.com logoRA Capital Management Increases Position in AveXis Inc. - Library For Smart Investors (NASDAQ:AVXS)
www.libraryforsmartinvestors.com - December 29 at 9:03 PM
News IconAnalysts showing optimistic trends for: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) (NASDAQ:AVXS)
avauncer.com - December 29 at 4:02 PM
streetinsider.com logoPre-Open Stock Movers 12/27: (CAPN) (IONS) (BIIB) Higher; (ELGX) (SGEN) (AVXS) Lower (more...) (NASDAQ:AVXS)
www.streetinsider.com - December 29 at 2:45 AM
insidermonkey.com logoAvexis Inc. (AVXS): RA Capital Management Ups Its Stake - Insider ... - Insider Monkey (blog) (NASDAQ:AVXS)
www.insidermonkey.com - December 27 at 4:01 PM
streetinsider.com logoAveXis (AVXS) Lower as FDA Approves Biogen's SPINRAZA with Broad Label; Stifel Says Highly Unlikely AVXS-101 ... - StreetInsider.com (NASDAQ:AVXS)
www.streetinsider.com - December 27 at 4:01 PM
einnews.com logoAvexis Inc Cmn Stk (AVXS) Showing Resistance Near $53.34 (NASDAQ:AVXS)
brazilbusiness.einnews.com - December 23 at 8:54 PM
schaeffersresearch.com logoStocks On the Move: GNC Holdings Inc, AveXis Inc, and Micron Technology, Inc. - Schaeffers Research (blog) (NASDAQ:AVXS)
www.schaeffersresearch.com - December 23 at 3:52 PM
reuters.com logoBRIEF-AveXis Inc to initiate study of AVXS-101 in SMA type 2 patients in Q... - Reuters (NASDAQ:AVXS)
www.reuters.com - December 22 at 3:48 PM
us.rd.yahoo.com logo4:02 pm AveXis says will use intended commercial GMP product in SMA Type 2 study; SMA Type 2 study to initiate in Q2 (NASDAQ:AVXS)
us.rd.yahoo.com - December 21 at 9:51 PM
reuters.com logoBRIEF-AveXis Inc to initiate study of AVXS-101 in SMA type 2 patients in Q2 (NASDAQ:AVXS)
www.reuters.com - December 21 at 4:48 PM
finance.yahoo.com logoAveXis to Use Intended Commercial GMP Product in SMA Type 2 Study (NASDAQ:AVXS)
finance.yahoo.com - December 21 at 4:48 PM
biz.yahoo.com logoAVEXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:AVXS)
biz.yahoo.com - December 21 at 4:48 PM
fool.com logo3 Reasons Biogen Inc. Stock Is Set to Soar in 2017 (NASDAQ:AVXS)
www.fool.com - December 20 at 9:04 PM
News IconMarket Scope: F-Score and Volatility Review for AveXis, Inc. (NASDAQ:AVXS) - The Business Journal (NASDAQ:AVXS)
belmontbusinessjournal.com - December 20 at 3:58 PM
News IconFinancial Update of AveXis, Inc. (NASDAQ:AVXS) - The Newburgh Press (NASDAQ:AVXS)
newburghpress.com - December 15 at 8:38 PM
News IconStock Survey: Viewing Levels for AveXis, Inc. (NASDAQ:AVXS) - The Business Journal (NASDAQ:AVXS)
belmontbusinessjournal.com - December 15 at 3:34 PM
insidermonkey.com logoHedge Funds Are Betting On AveXis Inc (AVXS) - Insider Monkey (blog) (NASDAQ:AVXS)
www.insidermonkey.com - December 15 at 3:34 PM
News IconAveXis Inc (AVXS) - The Next Biotech Blowup - Citron Research - ValueWalk (NASDAQ:AVXS)
www.valuewalk.com - December 15 at 3:34 PM
insidermonkey.com logoHedge Funds Are Betting On AveXis Inc (AVXS) (NASDAQ:AVXS)
www.insidermonkey.com - December 14 at 4:27 PM
News IconAveXis Inc (AVXS) – The Next Biotech Blowup – Citron Research (NASDAQ:AVXS)
www.valuewalk.com - December 14 at 4:27 PM
News IconShares in the Spotlight: AveXis, Inc. (NASDAQ:AVXS) - Marion Business Daily (NASDAQ:AVXS)
marionbusinessdaily.com - December 13 at 3:46 PM

Social

What is AveXis' stock symbol?

AveXis trades on the NASDAQ under the ticker symbol "AVXS."

Where is AveXis' stock going? Where will AveXis' stock price be in 2017?

7 brokerages have issued 12-month target prices for AveXis' stock. Their predictions range from $47.00 to $100.00. On average, they anticipate AveXis' stock price to reach $73.87 in the next year.

When will AveXis announce their earnings?

AveXis is scheduled to release their next quarterly earnings announcement on Tuesday, March, 14th 2017.

What are analysts saying about AveXis stock?

Here are some recent quotes from research analysts about AveXis stock:

  • According to Zacks Investment Research, "AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. " (2/14/2017)

  • Chardan Capital analysts commented, "On 23 December 2016, partners Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals (NASDAQ: IONS)), announced the US FDA approved Spinraza (nusinersen), a chronically-administered SMN2 antisense oligonucleotide for the treatment of spinal muscular atrophy (SMA) types 1 to 3. As discussed in our 27 December 2016 note, on efficacy, Figure 1 of the Spinraza label shows that 23% of SMA type 1 patients taking Spinraza died compared to 43% of untreated patients. We compare this to the phase I trial of AAV-based gene therapy (GT) AVXS-101 (a one-time treatment) from AveXis (Buy), where no SMA type 1 patients so far have died. On safety, as discussed in our 17 January 2017 industry note, the Spinraza label states that 11% of patients developed a platelet level below the lower limit of normal, compared to 0% of patients under sham treatment. Furthermore, as covered in both our 23 January 2017 industry note and in today's accompanying industry note, "Spinraza FDA review confirms our concerns of antisense platelet class effects", both Anthem Healthcare (unrated) and the FDA have expressed concerns regarding the safety of Spinraza."He added, "Considering the above efficacy and safety issues for Spinraza relative to AVXS-101, we reiterate our AVXS Buy rating, make AVXS a Chardan top pick for 2017, and increase our AVXS PT from $85 to $100 (+18%). We also open a pair trade of AVXS (long) and IONS (short), on the increasing potential for 1) AVXS-101 use in SMA types 2 and 3, likely at Spinraza's expense, and 2) Spinraza to increase the size of the SMA market ahead of an AVXS-101 launch." (1/26/2017)

Who owns AveXis stock?

AveXis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Deerfield Management Co. (8.08%), RA Capital Management, LLC (6.80%), Franklin Resources Inc. (4.32%), Boxer Capital LLC (3.72%) and RTW Investments LP (3.07%). Company insiders that own AveXis stock include Bong Y Koh, James E Flynn and Paul B Manning.

Who sold AveXis stock? Who is selling AveXis stock?

AveXis' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Janus Capital Management LLC and Renaissance Technologies LLC.

Who bought AveXis stock? Who is buying AveXis stock?

AveXis' stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Boxer Capital LLC, Perceptive Advisors LLC, State Street Corp, Franklin Resources Inc., RTW Investments LP, Russell Investments Group Ltd. and Pacad Investment Ltd.. Company insiders that have bought AveXis stock in the last two years include Bong Y Koh and James E Flynn.

How do I buy AveXis stock?

Shares of AveXis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of AveXis stock cost?

One share of AveXis stock can currently be purchased for approximately $57.51.

AveXis (NASDAQ:AVXS) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)

Earnings History Chart

Earnings by Quarter for AveXis (NASDAQ:AVXS)

Dividend History Chart

Dividend Payments by Quarter for AveXis (NASDAQ:AVXS)

Last Updated on 2/23/2017 by MarketBeat.com Staff